Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical reported its consolidated financial results for the nine months ending December 31, 2024, showing slight revenue stability but a decrease in core operating and net profits. Despite this, the company forecasts a significant improvement in operating and net profits for the year ending March 31, 2025, indicating strategic adjustments, including share repurchases and cancellations, to enhance shareholder value.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. They specialize in eye care products, focusing on developing and distributing medications for various ophthalmic conditions.
YTD Price Performance: -1.96%
Average Trading Volume: 1,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.47B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.
